TRVI Share Price | Trevi Therapeutics, Inc. Stock Analysis & Recommendation

Q: What does Trevi Therapeutics, Inc. do?

Overview: Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing nalbuphine ER for treating neurologically mediated conditions within the Pharmaceuticals & Biotechnology industry.Financial Snapshot: Most recent Net Profit: -10 Million (Quarterly Results - Mar 2025) Market cap: USD 729.17 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.04 Return on Equity: -47.61% Price to Book: 7.33Contact Details: Address: 195 Church St Fl 14, NEW HAVEN CT: 06510-2009 Tel: 1 203 3042499 Fax: 1 203 3042434 Website: http://www.trevitherapeutics.com/

Q: Is Trevi Therapeutics, Inc. technically bullish or bearish?

As of 9 September 2025, the technical trend for Trevi Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, and Bollinger Bands also indicate a bullish trend. Daily moving averages are bullish, while the KST shows bullish momentum on both weekly and monthly scales. Although the RSI is bearish on a monthly basis, the overall technical picture remains positive. In terms of performance, Trevi Therapeutics has significantly outperformed the S&P 500 over multiple periods, with a year-to-date return of 107.28% compared to the S&P 500's 12.22%, and a one-year return of 150.44% versus 17.14%.

Results Declared: Trevi Therapeutics, Inc. has declared results on 05 May 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

678.33 k

Shareholding (Mar 2026)

FII

10.83%

Held by 77 FIIs

DII

29.47%

Held by 39 DIIs

Promoter

34.53%

How big is Trevi Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Trevi Therapeutics, Inc. has a market capitalization of 729.17 million, categorizing it as a Micro Cap company. As of Jun 24, net sales for the latest four quarters are 0.00 million, with a net profit of -47.34 million.

View full answer

What does Trevi Therapeutics, Inc. do?

22-Jun-2025

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing nalbuphine ER for neurologically mediated conditions. As of March 2025, it has a market cap of $729.17 million and reported a net profit loss of $10 million.

View full answer

Who are in the management team of Trevi Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Trevi Therapeutics, Inc. includes Dr. David Meeker (Independent Chairman), Ms. Jennifer Good (President, CEO, Co-Founder, Director), and Directors Mr. Dominick Colangelo, Mr. Edward Mathers, Dr. James Cassella, and Mr. Michael Heffernan.

View full answer

Is Trevi Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Trevi Therapeutics, Inc. has shifted to a bullish trend with strong technical indicators, outperforming the S&P 500 significantly with a year-to-date return of 107.28% compared to 12.22%.

View full answer

Compare Trevi Therapeutics, Inc. with Similar Stocks

Vor Biopharma, Inc.Seer, Inc. (California)TriSalus Life Sciences, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1,431 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.03

Return on Equity

-24.16%

Price to Book

7.54

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2026)

Net Profit:

-13 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

22.6%

6 Months

27.61%

1 Year

110.96%

2 Years

384.48%

3 Years

334.98%

4 Years

505.6%

5 Years

569.05%

Trevi Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-21.84%

EBIT to Interest (avg)

-34.97

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.04

Sales to Capital Employed (avg)

Tax Ratio

0.07%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

7.54

EV to EBIT

-24.08

EV to EBITDA

-24.15

EV to Capital Employed

-255.30

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-24.16%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 40 Schemes (25.17%)

Foreign Institutions

Held by 77 Foreign Institutions (10.83%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is -28.16% vs 5.50% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.90",
          "val2": "-11.40",
          "chgp": "-30.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.20",
          "val2": "-10.30",
          "chgp": "-28.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 10.65% vs -64.60% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-49.20",
          "val2": "-51.40",
          "chgp": "4.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-42.80",
          "val2": "-47.90",
          "chgp": "10.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-14.90

-11.40

-30.70%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-13.20

-10.30

-28.16%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is -28.16% vs 5.50% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-49.20

-51.40

4.28%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-42.80

-47.90

10.65%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 10.65% vs -64.60% in Dec 2024

All Annual Results

Company CV

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat neurologically mediated conditions. The Company is engaged in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID), in patients with Parkinson’s disease. The Company is conducting a Phase 2b/3 clinical trial of nalbuphine ER. The Company has also commenced a Phase 1b clinical trial in patients with chronic liver disease to evaluate the safety, pharmacokinetics and anti-pruritic effect of nalbuphine ER in this population. The Company’s nalbuphine ER development programs are Chronic Pruritus Programs, Prurigo Nodularis Program, Pruritus in Chronic Liver Disease Program and Uremic Pruritus Program.

Company Coordinates

Company Details

195 Church St Fl 14 , NEW HAVEN CT : 06510-2009

Tel: 1 203 3042499

http://www.trevitherapeutics.com/

Registrar Details